Chemomab Therapeutics Ltd. Sponsored ADR CMMB
2.16
(0.04)
(1.82%)
as of 25 Sep
- Market cap
- $16.0M
- P/E
- 0.0×
Follow CMMB
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
10.49 | 9.08 | 10.31 | 6.41 |
Net Debt/EBITDA |
5.53 | 5.25 | 4.35 | 2.98 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 5.94 | 0.00 | 1.73 | |
Capex/Depreciation |
— | (0.04) | — | (0.14) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
0.00 | (1.75) | 0.00 | (0.47) | |
Cash per Share |
0.41 | 1.63 | 1.01 | 0.84 | |
Shareholders Equity per Share |
0.45 | 1.93 | 1.34 | 1.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.45 | 1.93 | 1.34 | 1.09 | |
Free Cash Flow |
— | (11.13) | — | (3.75) | |
Working Capital |
10.79 | 11.95 | 10.36 | 8.40 | |
Capital Expenditures |
— | 0.00 | — | 0.00 | |
Net Current Asset Value |
10.79 | 11.95 | 10.36 | 8.40 | |
| Other line items | |||||
Quick Ratio |
8.98 | 9.08 | 10.31 | 6.41 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | (1.75) | 0.00 | (0.47) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | 1.75 | 2.56 | 2.27 | |
Average Payables |
0.29 | 0.56 | 0.35 | 0.32 | |
Average Assets |
16.63 | 15.39 | 12.31 | 10.68 | |
Average Common Equity |
13.77 | 12.94 | 10.54 | 9.19 | |
Capex to Sales |
— | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates